Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
BioInvent
Candidate drug against HIV/AIDS approved to enter clinical trials in U.K.
June 15th, 2005
BioInvent (BINV) has obtained approval from the Medicines and Healthcare products Regulatory Agency in the U.K. to initiate the first clinical trial of BI-201, its drug candidate for the treatment of HIV-infected patients. This will be the first proprietary product from BioInvent's broad portfolio to enter clinical trials. The phase I/IIa trial includes 36 HIV-infected patients who have not received any previous treatment. The primary objective is to study safety, tolerability and pharmacokinetic properties of the candidate drug. A secondary objective is to study the effect on the viral load and thereby get the first indication as...
Source: Physician Law Weekly (2005-06-15)
|
